nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—CYP11B2—Hydrocortisone—psoriasis	0.25	0.301	CbGbCtD
Metyrapone—CYP11B1—Hydrocortisone—psoriasis	0.162	0.196	CbGbCtD
Metyrapone—CYP2A6—Methoxsalen—psoriasis	0.0869	0.105	CbGbCtD
Metyrapone—ABCC3—Cyclosporine—psoriasis	0.0853	0.103	CbGbCtD
Metyrapone—ABCC3—Methotrexate—psoriasis	0.0451	0.0544	CbGbCtD
Metyrapone—CYP2A6—Prednisolone—psoriasis	0.0423	0.0509	CbGbCtD
Metyrapone—CYP2A6—Dexamethasone—psoriasis	0.0249	0.03	CbGbCtD
Metyrapone—CYP3A4—Calcitriol—psoriasis	0.0224	0.0269	CbGbCtD
Metyrapone—CYP3A4—Methoxsalen—psoriasis	0.0174	0.021	CbGbCtD
Metyrapone—CYP2E1—Dexamethasone—psoriasis	0.0164	0.0198	CbGbCtD
Metyrapone—Niacin—HCAR2—psoriasis	0.0119	1	CrCbGaD
Metyrapone—CYP3A4—Cholecalciferol—psoriasis	0.0115	0.0139	CbGbCtD
Metyrapone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00999	0.012	CbGbCtD
Metyrapone—CYP3A4—Triamcinolone—psoriasis	0.00999	0.012	CbGbCtD
Metyrapone—CYP3A4—Betamethasone—psoriasis	0.00857	0.0103	CbGbCtD
Metyrapone—CYP3A4—Prednisolone—psoriasis	0.00845	0.0102	CbGbCtD
Metyrapone—CYP3A4—Hydrocortisone—psoriasis	0.00801	0.00966	CbGbCtD
Metyrapone—CYP3A4—Prednisone—psoriasis	0.00798	0.00962	CbGbCtD
Metyrapone—CYP3A4—Cyclosporine—psoriasis	0.00757	0.00912	CbGbCtD
Metyrapone—CYP3A4—Dexamethasone—psoriasis	0.00498	0.00601	CbGbCtD
Metyrapone—CYP11B2—ACE Inhibitor Pathway—REN—psoriasis	0.00392	0.0745	CbGpPWpGaD
Metyrapone—White blood cell count decreased—Acitretin—psoriasis	0.00363	0.0344	CcSEcCtD
Metyrapone—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00359	0.0682	CbGpPWpGaD
Metyrapone—Adrenal insufficiency—Prednisone—psoriasis	0.00304	0.0288	CcSEcCtD
Metyrapone—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00284	0.0539	CbGpPWpGaD
Metyrapone—CYP11B2—ACE Inhibitor Pathway—ACE—psoriasis	0.00245	0.0465	CbGpPWpGaD
Metyrapone—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00238	0.0451	CbGpPWpGaD
Metyrapone—CYP11B2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00235	0.0445	CbGpPWpGaD
Metyrapone—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00222	0.0423	CbGpPWpGaD
Metyrapone—Bone marrow depression—Hydroxyurea—psoriasis	0.0021	0.0199	CcSEcCtD
Metyrapone—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00205	0.0389	CbGpPWpGaD
Metyrapone—Hirsutism—Mycophenolic acid—psoriasis	0.00205	0.0194	CcSEcCtD
Metyrapone—CYP11B1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00202	0.0384	CbGpPWpGaD
Metyrapone—CYP11B2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00193	0.0366	CbGpPWpGaD
Metyrapone—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00176	0.0334	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—IVL—psoriasis	0.00171	0.0325	CbGpPWpGaD
Metyrapone—CYP11B1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00166	0.0315	CbGpPWpGaD
Metyrapone—Hirsutism—Cyclosporine—psoriasis	0.00166	0.0157	CcSEcCtD
Metyrapone—Hirsutism—Mycophenolate mofetil—psoriasis	0.00161	0.0153	CcSEcCtD
Metyrapone—Pain—Calcipotriol—psoriasis	0.00156	0.0148	CcSEcCtD
Metyrapone—Hirsutism—Prednisolone—psoriasis	0.00151	0.0143	CcSEcCtD
Metyrapone—Hirsutism—Hydrocortisone—psoriasis	0.00147	0.0139	CcSEcCtD
Metyrapone—Endocrine disorder—Mycophenolic acid—psoriasis	0.00143	0.0136	CcSEcCtD
Metyrapone—Alopecia—Clobetasol propionate—psoriasis	0.00142	0.0135	CcSEcCtD
Metyrapone—Bone marrow depression—Mycophenolate mofetil—psoriasis	0.00139	0.0132	CcSEcCtD
Metyrapone—Hirsutism—Triamcinolone—psoriasis	0.00139	0.0131	CcSEcCtD
Metyrapone—Hirsutism—Dexamethasone—psoriasis	0.00126	0.0119	CcSEcCtD
Metyrapone—Hirsutism—Betamethasone—psoriasis	0.00126	0.0119	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Clobetasol propionate—psoriasis	0.00118	0.0112	CcSEcCtD
Metyrapone—Dermatitis atopic—Prednisolone—psoriasis	0.00118	0.0112	CcSEcCtD
Metyrapone—ABCC3—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00118	0.0224	CbGpPWpGaD
Metyrapone—Pain—Tazarotene—psoriasis	0.00115	0.0109	CcSEcCtD
Metyrapone—Skin disorder—Clobetasol propionate—psoriasis	0.00111	0.0105	CcSEcCtD
Metyrapone—Hirsutism—Prednisone—psoriasis	0.00109	0.0104	CcSEcCtD
Metyrapone—Dermatitis atopic—Triamcinolone—psoriasis	0.00109	0.0103	CcSEcCtD
Metyrapone—Pancytopenia—Acitretin—psoriasis	0.00108	0.0102	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—psoriasis	0.00107	0.0101	CcSEcCtD
Metyrapone—Endocrine disorder—Hydrocortisone—psoriasis	0.00103	0.00977	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—CYP2S1—psoriasis	0.00102	0.0194	CbGpPWpGaD
Metyrapone—Nervous system disorder—Fluocinonide—psoriasis	0.00101	0.00958	CcSEcCtD
Metyrapone—CYP11B2—Metapathway biotransformation—CYP2S1—psoriasis	0.00101	0.0192	CbGpPWpGaD
Metyrapone—Skin disorder—Fluocinonide—psoriasis	0.001	0.00949	CcSEcCtD
Metyrapone—Pain—Clobetasol propionate—psoriasis	0.000977	0.00926	CcSEcCtD
Metyrapone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000924	0.0175	CbGpPWpGaD
Metyrapone—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000912	0.0173	CbGpPWpGaD
Metyrapone—Pain—Beclomethasone—psoriasis	0.00089	0.00843	CcSEcCtD
Metyrapone—CYP11B1—Biological oxidations—CYP2S1—psoriasis	0.000882	0.0167	CbGpPWpGaD
Metyrapone—Pain—Fluocinonide—psoriasis	0.000882	0.00835	CcSEcCtD
Metyrapone—CYP11B1—Metapathway biotransformation—CYP2S1—psoriasis	0.00087	0.0165	CbGpPWpGaD
Metyrapone—Dermatitis atopic—Prednisone—psoriasis	0.000859	0.00814	CcSEcCtD
Metyrapone—Pancytopenia—Hydroxyurea—psoriasis	0.000846	0.00801	CcSEcCtD
Metyrapone—Angiopathy—Acitretin—psoriasis	0.000824	0.00781	CcSEcCtD
Metyrapone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000816	0.0155	CbGpPWpGaD
Metyrapone—Alopecia—Acitretin—psoriasis	0.000802	0.0076	CcSEcCtD
Metyrapone—Alopecia—Fluocinolone Acetonide—psoriasis	0.0008	0.00758	CcSEcCtD
Metyrapone—Skin disorder—Methoxsalen—psoriasis	0.00079	0.00749	CcSEcCtD
Metyrapone—Bone marrow depression—Methotrexate—psoriasis	0.000787	0.00746	CcSEcCtD
Metyrapone—Endocrine disorder—Prednisone—psoriasis	0.000767	0.00727	CcSEcCtD
Metyrapone—Hypertension—Calcitriol—psoriasis	0.000767	0.00727	CcSEcCtD
Metyrapone—Hypotension—Methoxsalen—psoriasis	0.00076	0.0072	CcSEcCtD
Metyrapone—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000749	0.0142	CbGpPWpGaD
Metyrapone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00073	0.0139	CbGpPWpGaD
Metyrapone—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00072	0.0137	CbGpPWpGaD
Metyrapone—Headache—Clobetasol propionate—psoriasis	0.000716	0.00678	CcSEcCtD
Metyrapone—Pancytopenia—Mycophenolic acid—psoriasis	0.000708	0.00671	CcSEcCtD
Metyrapone—Skin disorder—Calcitriol—psoriasis	0.000704	0.00667	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Methoxsalen—psoriasis	0.000702	0.00666	CcSEcCtD
Metyrapone—Dizziness—Beclomethasone—psoriasis	0.000688	0.00652	CcSEcCtD
Metyrapone—Dizziness—Fluocinonide—psoriasis	0.000682	0.00646	CcSEcCtD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000677	0.0129	CbGpPWpGaD
Metyrapone—Headache—Beclomethasone—psoriasis	0.000652	0.00618	CcSEcCtD
Metyrapone—Angiopathy—Hydroxyurea—psoriasis	0.000647	0.00613	CcSEcCtD
Metyrapone—Headache—Fluocinonide—psoriasis	0.000646	0.00612	CcSEcCtD
Metyrapone—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.000631	0.00598	CcSEcCtD
Metyrapone—Alopecia—Hydroxyurea—psoriasis	0.00063	0.00597	CcSEcCtD
Metyrapone—Skin disorder—Acitretin—psoriasis	0.000627	0.00594	CcSEcCtD
Metyrapone—Pain—Calcitriol—psoriasis	0.00062	0.00588	CcSEcCtD
Metyrapone—Nausea—Beclomethasone—psoriasis	0.000618	0.00586	CcSEcCtD
Metyrapone—Gastrointestinal pain—Calcitriol—psoriasis	0.000593	0.00562	CcSEcCtD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000592	0.0112	CbGpPWpGaD
Metyrapone—Abdominal discomfort—Cyclosporine—psoriasis	0.000579	0.00548	CcSEcCtD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000578	0.011	CbGpPWpGaD
Metyrapone—Abdominal pain—Calcitriol—psoriasis	0.000573	0.00543	CcSEcCtD
Metyrapone—Pancytopenia—Mycophenolate mofetil—psoriasis	0.000559	0.0053	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Acitretin—psoriasis	0.000557	0.00528	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000555	0.00526	CcSEcCtD
Metyrapone—Pain—Acitretin—psoriasis	0.000552	0.00523	CcSEcCtD
Metyrapone—Pain—Fluocinolone Acetonide—psoriasis	0.00055	0.00521	CcSEcCtD
Metyrapone—Angiopathy—Mycophenolic acid—psoriasis	0.000542	0.00513	CcSEcCtD
Metyrapone—Dizziness—Methoxsalen—psoriasis	0.000538	0.0051	CcSEcCtD
Metyrapone—Alopecia—Mycophenolic acid—psoriasis	0.000528	0.005	CcSEcCtD
Metyrapone—Gastrointestinal pain—Acitretin—psoriasis	0.000528	0.005	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000525	0.00497	CcSEcCtD
Metyrapone—Abdominal pain—Acitretin—psoriasis	0.00051	0.00483	CcSEcCtD
Metyrapone—Headache—Methoxsalen—psoriasis	0.00051	0.00483	CcSEcCtD
Metyrapone—Nervous system disorder—Hydroxyurea—psoriasis	0.000497	0.00471	CcSEcCtD
Metyrapone—Skin disorder—Hydroxyurea—psoriasis	0.000492	0.00466	CcSEcCtD
Metyrapone—Nausea—Methoxsalen—psoriasis	0.000483	0.00458	CcSEcCtD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000472	0.00897	CbGpPWpGaD
Metyrapone—Vomiting—Calcitriol—psoriasis	0.000461	0.00437	CcSEcCtD
Metyrapone—Headache—Calcitriol—psoriasis	0.000454	0.0043	CcSEcCtD
Metyrapone—Hypertension—Mycophenolic acid—psoriasis	0.000449	0.00425	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000439	0.00416	CcSEcCtD
Metyrapone—Angiopathy—Cyclosporine—psoriasis	0.000438	0.00415	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000437	0.00414	CcSEcCtD
Metyrapone—Pain—Hydroxyurea—psoriasis	0.000433	0.0041	CcSEcCtD
Metyrapone—Nausea—Calcitriol—psoriasis	0.000431	0.00408	CcSEcCtD
Metyrapone—Angiopathy—Mycophenolate mofetil—psoriasis	0.000428	0.00405	CcSEcCtD
Metyrapone—Alopecia—Cyclosporine—psoriasis	0.000427	0.00404	CcSEcCtD
Metyrapone—Dizziness—Acitretin—psoriasis	0.000427	0.00404	CcSEcCtD
Metyrapone—Dizziness—Fluocinolone Acetonide—psoriasis	0.000425	0.00403	CcSEcCtD
Metyrapone—Alopecia—Mycophenolate mofetil—psoriasis	0.000416	0.00395	CcSEcCtD
Metyrapone—Nervous system disorder—Mycophenolic acid—psoriasis	0.000416	0.00394	CcSEcCtD
Metyrapone—Skin disorder—Mycophenolic acid—psoriasis	0.000412	0.0039	CcSEcCtD
Metyrapone—Vomiting—Acitretin—psoriasis	0.00041	0.00389	CcSEcCtD
Metyrapone—Vomiting—Fluocinolone Acetonide—psoriasis	0.000409	0.00388	CcSEcCtD
Metyrapone—Headache—Acitretin—psoriasis	0.000404	0.00383	CcSEcCtD
Metyrapone—Headache—Fluocinolone Acetonide—psoriasis	0.000403	0.00382	CcSEcCtD
Metyrapone—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000398	0.00756	CbGpPWpGaD
Metyrapone—Hypotension—Mycophenolic acid—psoriasis	0.000396	0.00376	CcSEcCtD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000383	0.00728	CbGpPWpGaD
Metyrapone—Nausea—Acitretin—psoriasis	0.000383	0.00363	CcSEcCtD
Metyrapone—Nausea—Fluocinolone Acetonide—psoriasis	0.000382	0.00362	CcSEcCtD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000369	0.00701	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000366	0.00347	CcSEcCtD
Metyrapone—Hypertension—Cyclosporine—psoriasis	0.000363	0.00344	CcSEcCtD
Metyrapone—Pain—Mycophenolic acid—psoriasis	0.000363	0.00344	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000356	0.00337	CcSEcCtD
Metyrapone—Hypertension—Mycophenolate mofetil—psoriasis	0.000354	0.00336	CcSEcCtD
Metyrapone—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000354	0.00672	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000347	0.00329	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000347	0.00329	CcSEcCtD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000339	0.00643	CbGpPWpGaD
Metyrapone—Nervous system disorder—Cyclosporine—psoriasis	0.000337	0.00319	CcSEcCtD
Metyrapone—Abdominal pain—Mycophenolic acid—psoriasis	0.000335	0.00318	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000335	0.00637	CbGpPWpGaD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000335	0.00636	CbGpPWpGaD
Metyrapone—Dizziness—Hydroxyurea—psoriasis	0.000335	0.00317	CcSEcCtD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000334	0.00635	CbGpPWpGaD
Metyrapone—Skin disorder—Cyclosporine—psoriasis	0.000333	0.00316	CcSEcCtD
Metyrapone—Angiopathy—Dexamethasone—psoriasis	0.000333	0.00315	CcSEcCtD
Metyrapone—Angiopathy—Betamethasone—psoriasis	0.000333	0.00315	CcSEcCtD
Metyrapone—Hypertension—Prednisolone—psoriasis	0.00033	0.00313	CcSEcCtD
Metyrapone—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000328	0.00311	CcSEcCtD
Metyrapone—Skin disorder—Mycophenolate mofetil—psoriasis	0.000325	0.00308	CcSEcCtD
Metyrapone—Alopecia—Dexamethasone—psoriasis	0.000324	0.00307	CcSEcCtD
Metyrapone—Alopecia—Betamethasone—psoriasis	0.000324	0.00307	CcSEcCtD
Metyrapone—Hypertension—Hydrocortisone—psoriasis	0.000323	0.00306	CcSEcCtD
Metyrapone—Vomiting—Hydroxyurea—psoriasis	0.000322	0.00305	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—psoriasis	0.00032	0.00303	CcSEcCtD
Metyrapone—Headache—Hydroxyurea—psoriasis	0.000317	0.00301	CcSEcCtD
Metyrapone—Pancytopenia—Methotrexate—psoriasis	0.000317	0.003	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000316	0.00601	CbGpPWpGaD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000316	0.00299	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000314	0.00597	CbGpPWpGaD
Metyrapone—Hypotension—Mycophenolate mofetil—psoriasis	0.000313	0.00296	CcSEcCtD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.00031	0.00589	CbGpPWpGaD
Metyrapone—Hypertension—Triamcinolone—psoriasis	0.000304	0.00288	CcSEcCtD
Metyrapone—Nausea—Hydroxyurea—psoriasis	0.000301	0.00285	CcSEcCtD
Metyrapone—Nervous system disorder—Hydrocortisone—psoriasis	0.000299	0.00283	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000296	0.00281	CcSEcCtD
Metyrapone—Skin disorder—Hydrocortisone—psoriasis	0.000296	0.00281	CcSEcCtD
Metyrapone—Pain—Cyclosporine—psoriasis	0.000293	0.00278	CcSEcCtD
Metyrapone—Angiopathy—Prednisone—psoriasis	0.00029	0.00275	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000289	0.00274	CcSEcCtD
Metyrapone—Pain—Mycophenolate mofetil—psoriasis	0.000286	0.00271	CcSEcCtD
Metyrapone—Hypotension—Hydrocortisone—psoriasis	0.000285	0.0027	CcSEcCtD
Metyrapone—Alopecia—Prednisone—psoriasis	0.000282	0.00267	CcSEcCtD
Metyrapone—Gastrointestinal pain—Cyclosporine—psoriasis	0.000281	0.00266	CcSEcCtD
Metyrapone—Dizziness—Mycophenolic acid—psoriasis	0.000281	0.00266	CcSEcCtD
Metyrapone—Hypertension—Betamethasone—psoriasis	0.000276	0.00261	CcSEcCtD
Metyrapone—Hypertension—Dexamethasone—psoriasis	0.000276	0.00261	CcSEcCtD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000275	0.00521	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000274	0.00259	CcSEcCtD
Metyrapone—Abdominal pain—Cyclosporine—psoriasis	0.000271	0.00257	CcSEcCtD
Metyrapone—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000271	0.00515	CbGpPWpGaD
Metyrapone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000271	0.00514	CbGpPWpGaD
Metyrapone—Vomiting—Mycophenolic acid—psoriasis	0.00027	0.00256	CcSEcCtD
Metyrapone—Pain—Prednisolone—psoriasis	0.000267	0.00253	CcSEcCtD
Metyrapone—Headache—Mycophenolic acid—psoriasis	0.000266	0.00252	CcSEcCtD
Metyrapone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000265	0.00251	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000263	0.00249	CcSEcCtD
Metyrapone—Pain—Hydrocortisone—psoriasis	0.000261	0.00247	CcSEcCtD
Metyrapone—Nervous system disorder—Betamethasone—psoriasis	0.000256	0.00242	CcSEcCtD
Metyrapone—Nervous system disorder—Dexamethasone—psoriasis	0.000256	0.00242	CcSEcCtD
Metyrapone—Nausea—Mycophenolic acid—psoriasis	0.000252	0.00239	CcSEcCtD
Metyrapone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000249	0.00236	CcSEcCtD
Metyrapone—Pain—Triamcinolone—psoriasis	0.000246	0.00233	CcSEcCtD
Metyrapone—Hypotension—Betamethasone—psoriasis	0.000244	0.00231	CcSEcCtD
Metyrapone—Hypotension—Dexamethasone—psoriasis	0.000244	0.00231	CcSEcCtD
Metyrapone—Angiopathy—Methotrexate—psoriasis	0.000242	0.00229	CcSEcCtD
Metyrapone—Abdominal pain—Hydrocortisone—psoriasis	0.000241	0.00228	CcSEcCtD
Metyrapone—Hypertension—Prednisone—psoriasis	0.00024	0.00227	CcSEcCtD
Metyrapone—Alopecia—Methotrexate—psoriasis	0.000236	0.00224	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000235	0.00223	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000234	0.00444	CbGpPWpGaD
Metyrapone—Dizziness—Cyclosporine—psoriasis	0.000227	0.00215	CcSEcCtD
Metyrapone—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	0.000226	0.0043	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—CXCL8—psoriasis	0.000226	0.00429	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Betamethasone—psoriasis	0.000225	0.00213	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000225	0.00213	CcSEcCtD
Metyrapone—Pain—Betamethasone—psoriasis	0.000223	0.00211	CcSEcCtD
Metyrapone—Pain—Dexamethasone—psoriasis	0.000223	0.00211	CcSEcCtD
Metyrapone—Nervous system disorder—Prednisone—psoriasis	0.000223	0.00211	CcSEcCtD
Metyrapone—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000221	0.00421	CbGpPWpGaD
Metyrapone—Dizziness—Mycophenolate mofetil—psoriasis	0.000221	0.0021	CcSEcCtD
Metyrapone—Skin disorder—Prednisone—psoriasis	0.00022	0.00209	CcSEcCtD
Metyrapone—Vomiting—Cyclosporine—psoriasis	0.000218	0.00207	CcSEcCtD
Metyrapone—Headache—Cyclosporine—psoriasis	0.000215	0.00204	CcSEcCtD
Metyrapone—Gastrointestinal pain—Betamethasone—psoriasis	0.000213	0.00202	CcSEcCtD
Metyrapone—Gastrointestinal pain—Dexamethasone—psoriasis	0.000213	0.00202	CcSEcCtD
Metyrapone—Vomiting—Mycophenolate mofetil—psoriasis	0.000213	0.00202	CcSEcCtD
Metyrapone—Headache—Mycophenolate mofetil—psoriasis	0.00021	0.00199	CcSEcCtD
Metyrapone—Dizziness—Prednisolone—psoriasis	0.000207	0.00196	CcSEcCtD
Metyrapone—Abdominal pain—Dexamethasone—psoriasis	0.000206	0.00195	CcSEcCtD
Metyrapone—Abdominal pain—Betamethasone—psoriasis	0.000206	0.00195	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—NDUFA5—psoriasis	0.000206	0.00391	CbGpPWpGaD
Metyrapone—Nausea—Cyclosporine—psoriasis	0.000204	0.00193	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—NFKB1—psoriasis	0.000202	0.00384	CbGpPWpGaD
Metyrapone—Dizziness—Hydrocortisone—psoriasis	0.000202	0.00191	CcSEcCtD
Metyrapone—Nausea—Mycophenolate mofetil—psoriasis	0.000199	0.00188	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000196	0.00186	CcSEcCtD
Metyrapone—Headache—Prednisolone—psoriasis	0.000196	0.00185	CcSEcCtD
Metyrapone—Vomiting—Hydrocortisone—psoriasis	0.000194	0.00184	CcSEcCtD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000192	0.00364	CbGpPWpGaD
Metyrapone—Headache—Hydrocortisone—psoriasis	0.000191	0.00181	CcSEcCtD
Metyrapone—Dizziness—Triamcinolone—psoriasis	0.00019	0.0018	CcSEcCtD
Metyrapone—Nervous system disorder—Methotrexate—psoriasis	0.000186	0.00176	CcSEcCtD
Metyrapone—Gastrointestinal pain—Prednisone—psoriasis	0.000186	0.00176	CcSEcCtD
Metyrapone—Nausea—Prednisolone—psoriasis	0.000186	0.00176	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—psoriasis	0.000184	0.00175	CcSEcCtD
Metyrapone—Vomiting—Triamcinolone—psoriasis	0.000183	0.00173	CcSEcCtD
Metyrapone—Nausea—Hydrocortisone—psoriasis	0.000181	0.00172	CcSEcCtD
Metyrapone—Headache—Triamcinolone—psoriasis	0.00018	0.0017	CcSEcCtD
Metyrapone—Abdominal pain—Prednisone—psoriasis	0.000179	0.0017	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—NDUFA5—psoriasis	0.000177	0.00337	CbGpPWpGaD
Metyrapone—Hypotension—Methotrexate—psoriasis	0.000177	0.00168	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—CYP2S1—psoriasis	0.000175	0.00332	CbGpPWpGaD
Metyrapone—Dizziness—Dexamethasone—psoriasis	0.000172	0.00163	CcSEcCtD
Metyrapone—Dizziness—Betamethasone—psoriasis	0.000172	0.00163	CcSEcCtD
Metyrapone—Nausea—Triamcinolone—psoriasis	0.000171	0.00162	CcSEcCtD
Metyrapone—Vomiting—Dexamethasone—psoriasis	0.000166	0.00157	CcSEcCtD
Metyrapone—Vomiting—Betamethasone—psoriasis	0.000166	0.00157	CcSEcCtD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000165	0.00314	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Methotrexate—psoriasis	0.000164	0.00155	CcSEcCtD
Metyrapone—Headache—Dexamethasone—psoriasis	0.000163	0.00155	CcSEcCtD
Metyrapone—Headache—Betamethasone—psoriasis	0.000163	0.00155	CcSEcCtD
Metyrapone—Pain—Methotrexate—psoriasis	0.000162	0.00154	CcSEcCtD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000156	0.00295	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Methotrexate—psoriasis	0.000155	0.00147	CcSEcCtD
Metyrapone—Nausea—Dexamethasone—psoriasis	0.000155	0.00147	CcSEcCtD
Metyrapone—Nausea—Betamethasone—psoriasis	0.000155	0.00147	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—CYP2S1—psoriasis	0.000151	0.00286	CbGpPWpGaD
Metyrapone—Dizziness—Prednisone—psoriasis	0.00015	0.00142	CcSEcCtD
Metyrapone—Abdominal pain—Methotrexate—psoriasis	0.00015	0.00142	CcSEcCtD
Metyrapone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000146	0.00277	CbGpPWpGaD
Metyrapone—Vomiting—Prednisone—psoriasis	0.000144	0.00137	CcSEcCtD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000144	0.00273	CbGpPWpGaD
Metyrapone—Headache—Prednisone—psoriasis	0.000142	0.00135	CcSEcCtD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000142	0.00269	CbGpPWpGaD
Metyrapone—Nausea—Prednisone—psoriasis	0.000135	0.00128	CcSEcCtD
Metyrapone—ABCC3—Metabolism—NDUFA5—psoriasis	0.000128	0.00243	CbGpPWpGaD
Metyrapone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000126	0.00239	CbGpPWpGaD
Metyrapone—Dizziness—Methotrexate—psoriasis	0.000125	0.00119	CcSEcCtD
Metyrapone—Vomiting—Methotrexate—psoriasis	0.000121	0.00114	CcSEcCtD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000119	0.00226	CbGpPWpGaD
Metyrapone—Headache—Methotrexate—psoriasis	0.000119	0.00113	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	0.000119	0.00225	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	0.000113	0.00215	CbGpPWpGaD
Metyrapone—Nausea—Methotrexate—psoriasis	0.000113	0.00107	CcSEcCtD
Metyrapone—ABCC3—Metabolism—CYP2S1—psoriasis	0.000109	0.00206	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000108	0.00206	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.17e-05	0.00174	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CARM1—psoriasis	8.55e-05	0.00162	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NDUFA5—psoriasis	8e-05	0.00152	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.99e-05	0.00152	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.9e-05	0.0015	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CARM1—psoriasis	7.36e-05	0.0014	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.88e-05	0.00131	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP2S1—psoriasis	6.8e-05	0.00129	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NDUFA5—psoriasis	6.32e-05	0.0012	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.69e-05	0.00108	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2S1—psoriasis	5.38e-05	0.00102	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CARM1—psoriasis	5.3e-05	0.00101	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CAT—psoriasis	5.26e-05	0.000998	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.96e-05	0.000942	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CAT—psoriasis	4.53e-05	0.00086	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—APOE—psoriasis	4.08e-05	0.000776	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PPARG—psoriasis	3.56e-05	0.000676	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—APOE—psoriasis	3.52e-05	0.000669	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CARM1—psoriasis	3.32e-05	0.000631	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CAT—psoriasis	3.26e-05	0.00062	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PPARG—psoriasis	3.07e-05	0.000582	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NDUFA5—psoriasis	2.93e-05	0.000557	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CARM1—psoriasis	2.63e-05	0.000499	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—APOE—psoriasis	2.53e-05	0.000481	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2S1—psoriasis	2.49e-05	0.000474	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PPARG—psoriasis	2.21e-05	0.000419	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CAT—psoriasis	2.04e-05	0.000388	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CAT—psoriasis	1.61e-05	0.000307	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—APOE—psoriasis	1.59e-05	0.000302	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PPARG—psoriasis	1.38e-05	0.000263	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—APOE—psoriasis	1.25e-05	0.000238	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CARM1—psoriasis	1.22e-05	0.000231	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPARG—psoriasis	1.09e-05	0.000208	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CAT—psoriasis	7.49e-06	0.000142	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—APOE—psoriasis	5.82e-06	0.000111	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPARG—psoriasis	5.07e-06	9.63e-05	CbGpPWpGaD
